Clinical trialNCT04739358TerminatedPhase 1/PHASE2Interventional

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

SponsorCriterium, Inc.Enrollment2Advanced Non-Small Cell Lung Cancer With MET Mutations

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer with central nervous system metastasis. In some patients, who have developed resistance to their tyrosine kinase inhibitors (TKIs), this study will look at how effective tepotinib is in combination with TKIs. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

David R Camidge, MD, PhD
University of Colorado, Denver
Principal Investigator
clinicaltrials.gov ↗
Tejas Patil, MD
University of Colorado, Denver
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Uc Davis Comprehensive Cancer Center
Sacramento, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
University of Washington
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tepotinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 May 2022
Primary completion: 23 Jun 2023
Completion: 23 Jun 2023
Last update posted: 18 Oct 2023
Registered enrollment: 2
Registry id: NCT04739358

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.